Joel Greenblatt acquired 5.54 Thousand Neurocrine Biosciences shares worth $763 Thousand. That's 0.01% of their equity portfolio (848th largest holding). The first Neurocrine Biosciences trade was made in Q1 2012. Since then Joel Greenblatt bought shares twelve more times and sold shares on eleven occasions. The stake costed the investor $529 Thousand, netting the investor a gain of 44% so far.